Abstract:Alzheimer's disease (AD) is one of the most common causes of cognitive impairment, and impairs social interaction and the quality of life for patients. Recently, management of blood pressure with antihypertensive drugs is reported to be effective for prevention of cognitive deficit; however, little is known about the effects of these drugs on AD. Telmisartan, an angiotensin II type1 (AT1) receptor blocker (ARB), is an unique antihypertensive agent with an agonistic action of peroxisome proliferator-activated receptor gamma (PPARγ). Activation of PPARγ has been reported to induce clearance of Aβ peptide and repression of β-secretase; therefore, PPARγ agonists have been expected for the prevention and possible treatment of AD. Here, we investigated the preventive effects of telmisartan on cognitive impairment in AD model mice. Male 8-week-old ddY mice were used for this study. Non-hypotensive dose of telmisartan and GW9662, a PPARγ antagonist, were administered in drinking water. Aβ1-40 was intracerebroventricularly injected 2 weeks after drug treatment. After 4 weeks of Aβ injection, cognitive function was evaluated by passive avoidance test and the Morris water maze. Expressions of mRNA in the brain were analyzed by real-time RT-PCR method. Regional cerebral blood flow was measured by two-dimensional blood blow meter. Concentration of Aβ in the brain was determined by ELISA. Immunohistochemical staining was used for detection of Aβ deposition in the brain. In both cognitive tests, Aβ-injection significantly impaired learning ability. However, pretreatment with telmisartan improved such cognitive decline to the control level. Moreover, pretreatment with telmisartan significantly enhanced cerebral blood flow and suppressed the mRNA expression of proinflammatory cytokine, TNF-α in the brain. Concentration and deposition of Aβ in the brain was markedly reduced by pretreatment with telmisartan. Interestingly, coadministration with GW9662 markedly decreased these beneficial effects of telmisartan. Treatment with GW9662 alone did not affect these parameters. Moreover, ARB without PPARγ antagonist showed less effect. These finding suggest that telmisartan has a preventive effects on cognitive decline in AD mouse model, at least in part due to possible synergistic PPARγ activation and AT1 receptor blockade, which would enhance-clearance of Aβ peptide and anti-inflammatory effects.

Multifunctional angiotensin II receptor blocker, telmisartan, prevents BBB breakdown and ameliorates cognitive impairment in type 2 diabetes mice with activation of PPAR-gamma

P1‐020: Multifunctional Angiotensin II Receptor Blocker, Telmisartan, Prevents BBB Breakdown and Ameliorates Cognitive Impairment in Type 2 Diabetes Mice with Activation of PPAR‐gamma

401 TELMISARTAN PREVENTS COGNITIVE DECLINE IN TYPE 2 DIABETIC MICE WITH IMPROVEMENT OF BLOOD-BRAIN BARRIER DISRUPTION PARTLY DUE TO PPAR-GAMMA ACTIVATION

Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.

P3‐271: Telmisartan, an Angiotensin II Receptor Blocker, Ameliorates Cognitive Impairment Induced by Amyloid Beta Injection Partly Due to Partial Agonistic Activation of PPAR‐gamma

Cognitive Deficit in Amyloid-Beta-Injected Mice Was Improved by Pretreatment with A Low Dose of Telmisartan Partly Because of Peroxisome Proliferator-Activated Receptor-Gamma Activation

Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.

O4‐01‐04: Beneficial Effects of Angiotensin II Receptor Blockers on Metabolic Disorder‐induced Cognitive Impairment

Telmisartan prevents high-fat diet-induced neurovascular impairments and reduces anxiety-like behavior

Effects of an angiotensin Ⅱ type 1 receptor blocker telmisartan on secretory function of β-cell in db/db mice

Telmisartan protects against high glucose/high lipid‐induced apoptosis and insulin secretion by reducing the oxidative and ER stress

P4‐206: Co‐treatment with Memantine and Compound 21, an Angiotensin II Type 2 Receptor Agonist, Prevents Cognitive Decline in Type 2 Diabetic Mice

Telmisartan ameliorates Aβ oligomer-induced inflammation via PPARγ/PTEN pathway in BV2 microglial cells

Effects of Telmisartan on the Expression of NADPH Oxidase in the Pancreatic Islet of Db/db Mice

Co-treatment with memantine and compound 21, an angiotensin II type 2 receptor agonist, prevents cognitive decline in type 2 diabetic mice

Possible Synergistic Effect of Direct Angiotensin II Type 2 Receptor Stimulation by Compound 21 with Memantine on Prevention of Cognitive Decline in Type 2 Diabetic Mice

Evaluation of nootropic activity of telmisartan and metformin on diazepam-induced cognitive dysfunction in mice through AMPK pathway and amelioration of hippocampal morphological alterations

The Effects of Telmisartan on Intra-Islet Microvasculature in Db/db Mice

Telmisartan Protects Mitochondrial Function, Gait, and Neuronal Apoptosis by Activating the Akt/GSK3β/PGC1α Pathway in an MPTP-Induced Mouse Model of Parkinson's Disease

Telmisartan Improves First-Phase Insulin Secretion in Vitro in Db/db Mice

Delayed Administration of Angiotensin II Type 2 Receptor (AT2R) Agonist Compound 21 Prevents the Development of Post-stroke Cognitive Impairment in Diabetes Through the Modulation of Microglia Polarization